Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Exp Neurol. 2009 Sep 4;223(1):153–165. doi: 10.1016/j.expneurol.2009.08.025

Table 1.

Animal groups and experimental design

Experimental animal groups Pre-labeling on SB (1st RL) Femoral lesion Administration of recombinant adenovirus Double labeling on SB and MB (2nd RL)
Double RL Sham - - - +
Non-Ad - transection - 3 weeks post-injury
Ad-NGF - transection 1 week post-injury 3 weeks post-injury
Sequential triple RL Sham + - - 4 or 9 weeks after 1st RL
Non-Ad 1 week pre-injury transection - 3 or 8 weeks post-injury
Ad-GFP 1 week pre-injury transection 1 week post-injury 3 weeks post-injury
Ad-NGF 1 week pre-injury transection 1 week post-injury 3 or 8 weeks post-injury
NGF Elisa or fluorescent imaging Ad-GFP - crush immediately post-injury -
Ad-NGF - crush Immediately post-injury -

RL, retrograde labeling; Ad, adenovirus; Non-Ad, non-adenovirus; Ad-NGF, recombinant adenovirus encoding NGF; Ad-GFP, recombinant adenovirus encoding GFP